Introduction
Antibodies which recognize specific intracellular and furthermore is found in the serum of patients who frequently suffer from aggressive renal and components are found in the serum of virtually all haematological disease. patients who have systemic lupus erythematosus (SLE). The origin of these autoantibodies remains uncertain, as does their role in the pathogenesis of SLE.1-3 A large number of such antibodies have been described such as anti-dsDNA and anti-Sm antibod- The clinical records of all patients who had antidisease-specific that they are now included in the PL 4 detected by counterimmunoelectrophoresis (CIE) revised diagnostic criteria for SLE published by the at the Hammersmith and at the Royal Free Hospitals American Rheumatism Association. 4 Other autoantibetween 1984 and 1991 were reviewed. Haemolytic bodies such as anti-Ro and anti-RNP are associated anaemia was considered to be present if the direct with several connective tissue diseases; although Coomb's test was positive and a reticulocytosis they are not disease-specific they help delineate (>5%) was present. Neutropenia was defined as groups of patients who may develop particular disrepeated neutrophil counts <2.0×109/l, lymphoease features. 1, 5 penia as counts <1.5×109/l and thrombocytopenia Bernstein and Bunn evaluated sera from over 1000 as platelet counts <100×109/l. Other causes of patients with various autoimmune diseases using haematological abnormalities, such as drug toxicity counterimmunoelectrophoresis and immunoprecipitor a haematinic deficiency, were excluded as far as ation. They detected an antibody which precipitated was possible. The presence of polymyositis was an antigen of 150 kDa which they called anti-PL 4 defined using the criteria of Bohan and Peter.18,19 in serum samples from six patients who had SLE. 6 The presence of lung fibrosis or interstitial pneumonIn this study, we present the first detailed descripitis was accepted if the patient had at least two of tion of the clinical and laboratory characteristics of the following: persistent bilateral crepitations on patients who have had anti-PL 4 detected in their auscultation, persistent bilateral shadowing on chest radiographs, or persistent pulmonary function test serum. Anti-PL 4 is highly specific for SLE (100%) abnormalities consistent with interstitial lung disease Results (VC<80%; TLCO<80% predicted).
Between 1984 and 1991, the serum from more than 50 000 patients with a wide spectrum of inflammatory diseases (rheumatoid arthritis, connective tissue
Laboratory procedures
diseases, glomerulonephritis, vasculitis, etc.) was Antinuclear antibodies were determined by indirect examined using CIE to detect antibodies against immunofluorescence, using rat liver or Hep-2 cells intra-cellular components. Sera from 1689 patients as substrate. Saline soluble antigen extracted from a with SLE, 879 patients with scleroderma and 256 commercially available rabbit thymus preparation patients with polymyositis were evaluated. Sera from (Pelfreez Biologicals) and a cytoplasmic human more than 2000 patients with osteoarthritis and from spleen fraction were used in a CIE assay to demonapproximately 100 normal controls were also screstrate precipitin lines of immunological identity with ened. Eighteen patients who had anti-PL 4 were appropriate reference sera as previously described.7
identified, all of whom had SLE. The prevalence of The identification of the anti-PL 4 was confirmed, in the antibody among patients with SLE is therefore 10 cases, by the identification of radiolabelled antiapproximately 1.0%. In 16 cases, detailed clinical gens in vivo; [35S]-methionine and [32P]-RNA HeLa information was available, and these patients were cell extracts were immunoprecipitated by proteinincluded in this study. The two cases who were A-sepharose-bound antibody and analysed by excluded had SLE, but both were lost to follow-up polyacrylamide gel electrophoresis (Figure 1 ).8 after a single consultation. All of the patients were IgM rheumatoid factor was assayed by latex fixafemale; at presentation the patients were aged tion (Ortho Diagnostics) and serum immunoglobulins between 12 and 65 years (median 30 years). Nine by radial immunodiffusion using commercial antipatients were Caucasian, five Black and two Arabic. sera. The C3 and C4 complement components were
The period of follow-up in a medical or rheumatology measured by radial immunodiffusion, and the total clinic after the onset of rheumatic symptoms ranged complement (CH50) by haemolytic assay. DNA bindfrom 2 to 10 years (median 4 years). ing was measured using a Farr assay. IgG and IgM antiphospholipid antibodies were detected by an
Clinical features
enzyme-linked immunosorbant assay.9
The principal clinical features observed in our patients are listed in Table 1 . All of our patients had 
SLE as defined by the American Rheumatism

Haematological manifestations
Association.4 Anti-PL 4 has not been detected in All of our patients had minor haematological abnorserum obtained from patients with other autoimmune malities, such as lymphopenia (100%), during the diseases or in serum from normal controls.
course of their disease. Four patients (25%) had normochromic normocytic anaemia of between 8
Skin disease and locomotor symptoms and 11 g/dl. Nine patients, detailed in Table 3 , had The majority (81%) of patients had photosensitive major haematological involvement which could not rashes, cutaneous vasculitis and alopecia. In addition, be attributed to drugs or infection (Hb<8.0 g/dl, one patient had livedo reticularis, one erythema neutrophils <1.0×109/l, platelets <100×109/l). multiforme and two patients urticarial vasculitis.
Serum ferritin, red-cell folate and vitamin B12 were Arthritis, tendonitis and dactylitis were common. normal in all of these patients. A bone-marrow Erosions of synovial joints were not detected by biopsy was obtained in 7/9 of these cases (patients plain radiography in any patient. Six patients 1-3, 6, 8 and 9 in Table 3 ); the cellularity and gross developed a Jaccoud-type arthropathy. Raynaud's haemopoiesis appeared normal in four, hypocellular phenomenon was reported in 13 cases but was not in two, while the number of plasma cells in the severe; no patient developed digital ulceration or bone marrow was increased in one patient resorption of their terminal phalanges.
(number 2). In four of the nine patients other major organ involvement (myositis 1/9, renal disease 3/9
Serositis, and involvement of the cardioand lung involvement 1/9) occurred at the same respiratory system time. In all cases (9/9), the haematological abnormalities improved following the introduction of, or an Serositis was a common feature; twelve patients (75%) suffered from episodes of pleurisy and six increase in the dose of, their steroids and/or immunosuppressants. Four cases (4/9) had a haematological from pericarditis. Three patients had pulmonary infarction, confirmed by ventilation/perfusion misrelapse when immunosuppression was withdrawn but improved again after a further increase in therapy. match, during an active phase of their disease; antibodies against phospholipids or the lupus antiThree patients required treatment with broad spectrum antibiotics during periods when their neutrophil coagulant were not detected in these patients. Two patients had episodes of carditis; one patient had a count was below 1.0×109/l. Two of three patients who had a pancytopenia coronary vasculitis and developed first degree heart block. Clinical, radiological and pulmonary function presented with no other clinical signs to indicate that they suffered from a connective tissue disease test abnormalities consistent with lung fibrosis were seen in two patients. Three patients developed the (patients 3 and 6 in Table 3 ); other clinical features of SLE developed after 1 year and 18 months. In shrinking lung syndrome (clear chest radiographs with high diaphragms, progressive reduction in lung both patients, anti-PL 4 was the sole ENA detected and was important in allowing an early diagnosis to volumes with preservation of the corrected transfer factor).
be made. In addition, four patients developed significant
Renal disease leucopenia (WBC between 1.2 and 2.0×109/l) during treatment with cyclophosphamide, which did Renal involvement was common. Twelve patients not recur after the dose was decreased. had one or more episodes of glomerulonephritis; all such patients had active urinary sediments and proteinuria which ranged from 0.5 g/24 h to 7 g/24 h.
Other organ involvement
The renal histological findings in nine patients who Generalized lymphadenopathy was detected in 75% had a renal biopsy are summarized in Table 2 .
of the cases. The presence of lymphadenopathy was associated with active SLE and settled following immunosuppression; no lymph-node biopsies were examined. Two of the patients with abnormal liver complained of episodes of slurred speech and leftbodies detected by CIE (Table 4) including anti-RNP, anti-Sm, anti-Ro, anti-La and anti-Ku. Three patients sided weakness; a CT scan was normal but an MRI scan demonstrated diffuse white-matter lesions. Two had high titre anti-phospholipid antibodies but did not suffer from thrombotic disorders. One patient patients with central nervous system disease and a further four patients without other central nervous who had anti-Ro and anti-La had prominent sicca symptoms. system involvement suffered from recurrent migraines.
In all but one case, anti-PL 4 could only be detected in patients' serum by counterimmunoelectrophoresis during phases when their SLE was active.
Laboratory features
This result was statistically significant using Fisher's Table 4 
Treatment and outcome
patients had a raised ESR, raised immunoglobulins, reduced total haemolytic complement and reduced Table 5 summarizes the treatments given to our complement components C3 and C4. Four patients patients and the outcome. All patients required had abnormal liver function tests, two had evidence treatment with high doses of prednisolone of an autoimmune hepatitis on needle biopsy.
(40-60 mg/day). Twelve patients also received cyclophosphamide either as monthly i.v. pulses or as
Serological findings
Serum from all of our patients contained anti-nuclear antibodies (ANA) as well as anti-PL 4 antibodies; of anti-PL 4 helped to make a diagnosis of SLE; the Dialysis-dependent 3 19 haematological abnormalities responded to treatment
Chronic renal failure (no dialysis) 2 13
with steroids and pulsed intravenous cyclophosWell off treatment 1 6 phamide. Anti-PL 4 binds to a 150 kDa polypeptide, which may also be detected by Western blotting. Figure 1 continuous oral therapy for approximately 6 months; azathioprine (125-175 mg/day) was then substituted.
shows the results of immunoprecipitation and compares anti-PL 4 to the anti-RNA polymerase III Despite treatment with high-dose steroids/cyclophosphamide, and in one case plasmapheresis, three antibody system. There are two other rare antibodyantigen systems which have been found in associpatients died of their disease. Seven patients remain well on treatment (prednisolone 7.5-20 mg/day and ation with SLE; designated by Treadwell et al. antiSu and anti-Me. However both immunodiffusion and azathioprine 125-175 mg/day and one patient remains well off all treatment. Three patients who immunoprecipitation demonstrate that anti-Su, antiMe and anti-PL 4 are all distinct autoantibodies; suffered from diffuse proliferative glomerulonephritis remain dialysis-dependent. One patient developed anti-Su recognizes a 50-55 kDa antigen,10,11 antiMe recognizes four peptides between 100 and chronic renal failure despite high-dose steroid and cyclophosphamide therapy. Two patients presented 16 kDa.12 Further studies are required to analyse the nature of the PL 4 antigen system. to our hospitals with established chronic renal impairment (creatinine clearance 10-20 ml/min, cre-
The clinical features (Table 1 ) seen in our patients who had anti-PL 4 are similar to those reported in atinine >600 mmol/l) and remain dialysisdependent. many large series of SLE patients.13,14 However anti-PL 4 appears to identify a subset of SLE patients who
Infection
have a particular propensity to develop severe haematological and renal abnormalities. Twenty-one episodes of sepsis requiring admisAlthough haematological manifestations were sion to hospital were reported among 12 patients common and relatively serious, they typically (bacterial infection 8, culture negative 8, cytoresponded well to treatment. Severe neutropenia megalovirus 2, Pneumocystis carinii 1, other fungal (neutrophil <1.0×109/l) unrelated to treatment, was infections 2). Infection was an important factor in all seen in 4/16 of our patients with anti-PL 4. By three patients who have died. One patient, with comparison, Nossent and colleagues studied 126 active glomerulonephritis died of respiratory failure patients with SLE prospectively;15 and observed after contracting pneumonia. One patient died from severe neutropenia (<1.0×109/l) in only five of sepsis due to a perforated diverticula abcess. One their patients (x2=7.33; p=0.007). Thrombopatient died from a combination of disseminated cytopenia (44%) and pancytopenia (30%) were candida and cytomegalovirus pneumonitis. All of also more common in patients with anti-PL 4 these patients had received high doses of prednisothan is generally seen in SLE. The European working lone and immunosuppressants within 12 months of party on SLE studied 1000 consecutive patients with their final illnesses.
SLE who did not have anti-PL 4 antibodies;13 significant thrombocytopenia was seen in only (22%) 220/1000 patients compared to 7/16 patients in our Discussion series (x2=42.9; p<0.001). Severe haematological disease, particularly thrombocytopenia, is recognized Anti-PL 4 is a rare autoantibody; it was detectable in the sera of only 1.0% of our SLE population as a marker of severe SLE and is associated with a decreased survival.15,16 (18/1700). Anti-PL 4 was not been detected in the serum of normal controls or in patients with other Twelve patients (75%) had significant renal an important factor in the death of three patients.
clinical and immunologic patterns of disease expression in a
The treatment given to these patients for their under- factor for infection. The activity of SLE as judged by
